The Lancet (2020). [3] Laser treatment of benign prostate enlargement—which laser for which prostate?. Nature Reviews Urology (2014).

Benign Prostatic Hyperplasia (BPH) occurs when the prostate gland grows larger, pressing against the urethra. This pressure narrows the urethra, making it harder for urine to pass through.

Symptoms related to BPH are present in about one in four men by age 55, and in half of 75-year-old men. However, treatment is only necessary if symptoms become bothersome.

Of the agents that interfere with testosterone's stimulatory effect on prostate size, finasteride, a 5-α-reductase inhibitor, is the only one with FDA-approved labeling for BPH treatment.

Kaplan, S. A., et al. (2023) The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms ...

GREENBRAE, Calif.-- (BUSINESS WIRE)--MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH).

Symptomatic BPH and prostatitis affect over 100 million men worldwide, resulting in painful symptoms and lower quality of life. Laser-based devices and urethral implants are expected to be the ...

Benign prostatic hyperplasia (BPH) remains a significant clinical condition affecting ageing men worldwide, characterised by enlargement of the prostate gland and associated lower urinary tract ...

However, these adverse reactions are dose related and reported more frequently with higher dosages (i.e., 10-20 mg/day). [22, 69] Since lower doses of alfuzosin are used for the treatment of BPH ...